Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Should COVID-19 Quantitative Antibody Titers be Implemented to Guide COVID-19 Booster Vaccinations Regardless of HIV Status, Immunosuppression, or Age?

NCT05104359 is registered in ClinicalTrials.gov with Epividian as lead sponsor.

NCT NCT05104359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Should COVID-19 Quantitative Antibody Titers be Implemented to Guide COVID-19 Booster Vaccinations Regardless of HIV Status, Immunosuppression, or Age?
Lead sponsor
Epividian
Phase
Observational
Overall status
Completed
Start date
December 11, 2020
Completion date
April 30, 2022
Enrollment
825 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 vaccines, immunogenicity, vaccine